ArticleMaterials horizons2022
Selective treatment of intracellular bacterial infections using host cell-targeted bioorthogonal nanozymes.
Article in Materials horizons, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 47 citations in OpenAlex.
- Antimicrobial peptides isolated from probiotics as an alternative to antibiotics againstApplied and environmental microbiology · 2026Article
- Harnessing nanozymes as next-generation antimicrobial agents: From mechanisms to therapeutic strategies.Materials today. Bio · 2025Article
- Evolving strategies of intracellular HypervirulentVirulence · 2025Article
- Harnessing intracellular bacteria in bladder by intravesical delivery of antibiotics-loaded nanodiamonds to reduce the recurrence of urinary tract infection.Journal of nanobiotechnology · 2025Article
- Exploring New Bioorthogonal Catalysts: Scaffold Diversity in Catalysis for Chemical Biology.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Bioorthogonal catalysis for antimicrobial therapy.MedMat · 2024Article
- Targeting Intracellular Bacteria with Dual Drug-loaded Lactoferrin Nanoparticles.ACS infectious diseases · 2024Article
- Modular Fabrication of Bioorthogonal Nanozymes for Biomedical Applications.Advanced materials (Deerfield Beach, Fla.) · 2024Review
- Modulation of Gold Nanoparticle Ligand Structure-Dynamic Relationships Probed Using Solution NMR.ACS nanoscience Au · 2024Article
- Polarization of macrophages to an anti-cancer phenotype throughChemical science · 2024Article
- Biomimetic and bioorthogonal nanozymes for biomedical applications.Nano convergence · 2023Review
- Biodegradable nanoemulsion-based bioorthogonal nanocatalysts for intracellular generation of anticancer therapeutics.Nanoscale · 2023Article
- Interfacing Nanomaterials with Biology through Ligand Engineering.Accounts of chemical research · 2023Article
- Bioorthogonal nanozymes for breast cancer imaging and therapy.Journal of controlled release : official journal of the Controlled Release Society · 2023Article
- Inorganic nanoparticles as scaffolds for bioorthogonal catalysts.Advanced drug delivery reviews · 2023Review
- Biodegradable Antibacterial Bioorthogonal Polymeric Nanocatalysts Prepared by Flash Nanoprecipitation.ACS applied materials & interfaces · 2023Article
- The recent development of nanozymes for targeting antibacterial, anticancer and antioxidant applications.RSC advances · 2023Review
- All-natural gelatin-based bioorthogonal catalysts for efficient eradication of bacterial biofilms.Chemical science · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
Intracellular bacterial infections are difficult to treat, and in the case of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.